| Evidence for Gastrointestinal Infection of SARS-CoV-2 | Gastroenterology | 2020 | 1.6K |
| Liver injury in COVID-19: management and challenges | The Lancet Gastroenterology and Hepatology | 2020 | 1K |
| Prolonged presence of SARS-CoV-2 viral RNA in faecal samples | The Lancet Gastroenterology and Hepatology | 2020 | 973 |
| Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study | American Journal of Gastroenterology | 2020 | 960 |
| Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis | Gastroenterology | 2020 | 833 |
| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement | Journal of Hepatology | 2020 | 764 |
| MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease | Gastroenterology | 2020 | 748 |
| Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization | Gastroenterology | 2020 | 555 |
| Liver injury during highly pathogenic human coronavirus infections | Liver International | 2020 | 504 |
| Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? | The Lancet Gastroenterology and Hepatology | 2020 | 504 |
| Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 498 |
| Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission | Alimentary Pharmacology and Therapeutics | 2020 | 496 |
| COVID-19: Abnormal liver function tests | Journal of Hepatology | 2020 | 453 |
| The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 448 |
| Clinical Features of COVID-19-Related Liver Functional Abnormality | Clinical Gastroenterology and Hepatology | 2020 | 439 |
| Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic | Liver Transplantation | 2020 | 426 |
| Covid-19 and the digestive system | Journal of Gastroenterology and Hepatology (Australia) | 2020 | 398 |
| Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry | Gastroenterology | 2020 | 396 |
| Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology and Hepatology | 2020 | 355 |
| Gut microbiota-derived metabolites as key actors in inflammatory bowel disease | Nature Reviews Gastroenterology and Hepatology | 2020 | 318 |
| Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes | American Journal of Gastroenterology | 2020 | 315 |
| ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection | Clinical Gastroenterology and Hepatology | 2020 | 315 |
| SARS-CoV-2 in wastewater: potential health risk, but also data source | The Lancet Gastroenterology and Hepatology | 2020 | 301 |
| The gut-liver axis in liver disease: Pathophysiological basis for therapy | Journal of Hepatology | 2020 | 300 |
| The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 297 |
